Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10343530 | 0.86 | TLR8 (0.58) | TLR8HPGDMAPK1TLR7KDM4E | |
| SCHEMBL10345106 | 0.82 | TLR8 (0.48) | TLR8HPGDMAPK1TLR7KDM4E | |
| SCHEMBL10343412 | 0.81 | TLR8 (0.49) | TLR8HPGDMAPK1TLR7KDM4E | |
| SCHEMBL10343179 | 0.81 | TLR8 (0.51) | TLR8HPGDMAPK1TLR7KDM4E | |
| SCHEMBL10325503 | 0.80 | TLR8 (0.56) | TLR8HPGDMAPK1TLR7KDM4E | |
| SCHEMBL10343180 | 0.79 | TLR8 (0.49) | TLR8HPGDMAPK1TLR7KDM4E | |
| SCHEMBL10325898 | 0.79 | TLR8 (0.57) | TLR8HPGDMAPK1TLR7POLB | |
| SCHEMBL10345362 | 0.79 | TLR8 (0.47) | TLR8HPGDMAPK1TLR7KDM4E | |
| SCHEMBL18297269 | 0.78 | TLR8 (0.49) | TLR8HPGDMAPK1TLR7KDM4E | |
| SCHEMBL15499091 | 0.78 | TLR8 (0.58) | TLR8HPGDMAPK1TLR7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210347911-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347911-A1 | ANTI-HER2 COMBINATIONS FOR TREATING TUMORS | ERBB2, EGFR, ERBB3 | TLR8 900/4885HPGD 1850/4885MAPK1 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.